
Product Data Sheet

Product Name: TY-51469

Cat. No.: GC32004

Chemical Properties

Cas. No. 603987-59-3

SMILES O=C(C1=CSC(C2=CC=C(NS(=O))(C3=C(C)C4=CC(F)=CC=C4S3)=O)C(S(=O)(C)=O)=C2)=N1)OFormula C₂₀H₁₅FN₂O₆S₄

M.Wt 526.6

Solubility DMSO : 33.33 mg/mL (63.29 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Protocol****Animal experiment:**

Rats[1] The 2-week intravenous repeated-dose toxicity study of TY-51469 was conducted in male Sprague-Dawley rats at daily doses of 0 (control), 20, and 60 mg/kg[1]. Mice[1] the chymase inhibitor TY-51469 was administered daily at a dose of 0.1 or 1.0 mg/kg/day for 21 days using an osmotic pump to male 8-week-old ICR mice. The osmotic pump released the drug solution continuously at a rate of 0.3 μL/h for 21 days[2].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

[1]. Takato H, et al. The specific chymase inhibitor TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice. Expert Opinion on Therapeutic Targets Volume 15, 2011 - Issue 4.

Background

TY-51469 is a chymase inhibitor with IC50s for simian and human chymases of 0.4 and 7.0 nM, respectively.

TY-51469 shows 100% stability in rat plasma at 40°C for as long as 1 hour[1]. TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice[2].

[1]. Takato H, et al. The specific chymase inhibitor TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice. Expert Opinion on Therapeutic Targets Volume 15, 2011 - Issue 4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA